Uncategorized

Ryvu Therapeutics Presents Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Ryvu Therapeutics announced presentations of preclinical data from the PRMT5 program and synthetic lethality platform, as well as preclinical data on MEN1703 in B-cell lymphomas, at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place in Boston, Massachusetts.

Ryvu Therapeutics Presents Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Read More »

Scroll to Top